Tilray Stock: Buy Ahead Of Earnings?

TheStreet2021-07-27

On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity. Drug manufacturer Tilray,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（10）

Cvt
·2021-07-28
Great [Smile]
Reply
4
Report
BBKK
·2021-07-28
Wow
Reply
1
Report
Fold Replies
- Dbw:
  yeah wow
  2021-07-28
  Reply
  Report
claratan
·2021-07-28
Wow ??
Reply
1
Report
Fold Replies
- WeiChyi:
  K
  2021-07-28
  Reply
  Report
SaberNoTooth
·2021-07-28
pls like. thanks
Reply
1
Report
Derrickmin
·2021-07-28
Oh
Reply
2
Report
RyanLJW
·2021-07-28
Amazing
Reply
3
Report
eggyoke99
·2021-07-27
yeah
Reply
3
Report
PanaCota
·2021-07-27
Oo
Reply
4
Report
Fold Replies
- BBBBBBBBBB:
  Hi
  2021-07-28
  Reply
  Report
Chrissssy
·2021-07-27
Like and comment please:)
Reply
4
Report
Fold Replies
- Derrickmin:
  Done
  2021-07-28
  Reply
  Report
- ykang:
  buy！
  2021-07-27
  Reply
  Report
kukumolu
·2021-07-27
It should rise after the FUD
Reply
3
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1134472085?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-07-27 23:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134472085","market":"us","top_or_hot":-1,"title":"Tilray Stock: Buy Ahead Of Earnings?","media":"TheStreet","content":"<div>\n<p>On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.\nDrug manufacturer Tilray,...</p>\n\n<a href=\"https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings\">Source Link</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray Stock: Buy Ahead Of Earnings?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray Stock: Buy Ahead Of Earnings?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 23:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.\nDrug manufacturer Tilray,...</p>\n\n<a href=\"https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TLRY","symbol_name":"Tilray Inc.","start_time":0,"source_url":"https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings","article_id":"1134472085","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134472085","pubTimestamp":1627398407,"sourceInfo":null,"weMediaInfo":null,"summary":"On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. ","collect":0,"end_time":0,"defaultTopTitle":"thestreet.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"TLRY":"Tilray Inc."},"translate_title":"Tilray股票：在收益前买入？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLRY":0.9},"content_text":"On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.\nDrug manufacturer Tilray, a Canadian-based company engaged in research, cultivation, and distribution of medical cannabis, is about to report its fiscal fourth quarter results.\nThe stock has been popular among Redditors in 2021. With earnings day around the corner, the question now is whether TLRY might be a good buy at current prices.\nThe cannabis market\nIn the United States, a total of 34 states plus the District of Columbia consider marijuana legal for medicinal use. Among these, 16 have approved recreational use,according to the latest data.\nIn 2020, the cannabis market was estimated to be valued at $20 billion by New Frontier Data, and it is projected to reach $43 billion by 2025. Growth seems to be fueled by social acceptance of cannabis and the development of a regulatory framework for production.\nFigure 1: Annual growth of the U.S legal cannabis industry.\nTilray + Aphria merger\nTilray has been trading publicly since December 2020, after merging with Aphria. Following the deal, TLRY now has a market cap of close to $6 billion – one of the largest cannabis companies today, alongside peer Canopy Growth.\nThe Tilray-Aphria merger was justified by expected benefits that included:\n\nmarket leadership in Canada\nfoothold in Europe and better positioning in the U.S.\nlower production costs and synergies\n\nFigure 2: Aphria + Tilray merger.\nWall Street's take\nIn the past several quarters, Tilray has been making good strides on its P&L. In 2020, the company reported progressively better revenue that reached $210 million for the year. It also managed to reverse a sharp net loss position that had been accumulating since prior to last year. See below:\nFigure 3: Tilray earnings and revenues.\nAnalysts currently rate TLRY as a moderate buy, with an average target price of nearly $21 for a potential upside of 52%. The merger with Aphria weighed positively for most analysts.\nDespite the encouraging metrics, some of Wall Street’s commentary around the company and stock has been cautious lately. Last month, Cowen & Co.’s analyst maintained her buy recommendation, but stated the following about Tilray:\n\n \"We are taking down our revenue and EBITDA estimates, as we expect COVID challenges in Canada to remain a headwind. In addition, TLRY faces tough market share comps, where it has retraced from peak levels to stabilize following the completion of the merger with Aphria.”\n\nAlliance Global Partners has a neutral recommendation on TLRY. Less optimistic, the analyst has lowered the target price from $32 to $18.Accordingto him, the merger with Aphria is beneficial for the stock, but the price is fair at current levels.\nReddit popularity\nTilray stock witnessed an eye-popping rally in February 2021. Shares climbed more than 670% between early January and early February, before pulling back sharply.\nThe drivers of bullishness were (1) good earnings results, (2) favorable developments in cannabis regulation, and (2) the signed agreement with Grow Pharma to distribute medical cannabis for patients in the U.K.\nReddit forums certainly seem to have played a role as well. Meme mania picked up steam in late January, at first with GameStop. Soon enough, other stocks like TLRY also benefited. See below the share price history, alongside the volume of comments on WallStreetBets.\nFigure 4: TLRY stock sentiment and popularity on the WSB.\nWall Street Memes’ take\nThe cannabis industry is very sensitive to regulatory factors. Lack of positive news regarding new cannabis regulations can lead to prolonged periods of malaise in stock price, like the current one. In addition, Tilray faces the usual integration risks, following the recent merger.\nAt the same time, opportunities continue to exist as medicinal and recreational use of cannabis in the U.S and elsewhere globally expand. Judging by stock ratings and price targets, Wall Street analysts still seem optimistic about the stock. Lastly, with the Reddit crowd paying attention, TLRY could potentially become the target of a meme attack again in the future.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":803120297,"gmtCreate":1627428789019,"gmtModify":1703489623964,"author":{"id":"3579235597126488","authorId":"3579235597126488","name":"Cvt","avatar":"https://static.tigerbbs.com/c8fda02901ec7a98b51fe8e84d016ab2","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Great [Smile]&nbsp;","listText":"Great [Smile]&nbsp;","text":"Great [Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/803120297","repostId":1134472085,"repostType":4,"repost":{"id":"1134472085","pubTimestamp":1627398407,"share":"https://www.laohu8.com/m/news/1134472085?lang=&edition=full","pubTime":"2021-07-27 23:06","market":"us","language":"en","title":"Tilray Stock: Buy Ahead Of Earnings?","url":"https://stock-news.laohu8.com/highlight/detail?id=1134472085","media":"TheStreet","summary":"On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. ","content":"<p>On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.</p>\n<p>Drug manufacturer Tilray, a Canadian-based company engaged in research, cultivation, and distribution of medical cannabis, is about to report its fiscal fourth quarter results.</p>\n<p>The stock has been popular among Redditors in 2021. With earnings day around the corner, the question now is whether TLRY might be a good buy at current prices.</p>\n<p><b>The cannabis market</b></p>\n<p>In the United States, a total of 34 states plus the District of Columbia consider marijuana legal for medicinal use. Among these, 16 have approved recreational use,according&nbsp;to the latest data.</p>\n<p>In 2020, the cannabis market was&nbsp;estimated&nbsp;to be valued at $20 billion by New Frontier Data, and it is projected to reach $43 billion by 2025. Growth seems to be fueled by social acceptance of cannabis and the development of a regulatory framework for production.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/703f3ea081e0c6f7d74ae53891810b24\" tg-width=\"1240\" tg-height=\"859\" width=\"100%\" height=\"auto\"><span>Figure 1: Annual growth of the U.S legal cannabis industry.</span></p>\n<p><b>Tilray + Aphria merger</b></p>\n<p>Tilray has been trading publicly since December 2020, after merging with Aphria. Following the deal, TLRY now has a market cap of close to $6 billion – one of the largest cannabis companies today, alongside peer Canopy Growth.</p>\n<p>The Tilray-Aphria merger was justified by expected benefits that included:</p>\n<ol>\n <li>market leadership in Canada</li>\n <li>foothold in Europe and better positioning in the U.S.</li>\n <li>lower production costs and synergies</li>\n</ol>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b6577d25764f8877328fad35a1d14e2d\" tg-width=\"1240\" tg-height=\"659\" width=\"100%\" height=\"auto\"><span>Figure 2: Aphria + Tilray merger.</span></p>\n<p><b>Wall Street's take</b></p>\n<p>In the past several quarters, Tilray has been making good strides on its P&amp;L. In 2020, the company reported progressively better revenue that reached $210 million for the year. It also managed to reverse a sharp net loss position that had been accumulating since prior to last year. See below:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2ee35f0e1943629cac6c9a31ffdb5ca8\" tg-width=\"1240\" tg-height=\"481\" width=\"100%\" height=\"auto\"><span>Figure 3: Tilray earnings and revenues.</span></p>\n<p>Analysts currently rate TLRY as a moderate buy, with an average target price of nearly $21 for a potential upside of 52%. The merger with Aphria weighed positively for most analysts.</p>\n<p>Despite the encouraging metrics, some of Wall Street’s commentary around the company and stock has been cautious lately. Last month, Cowen &amp; Co.’s analyst&nbsp;maintained&nbsp;her buy recommendation, but stated the following about Tilray:</p>\n<blockquote>\n \"We are taking down our revenue and EBITDA estimates, as we expect COVID challenges in Canada to remain a headwind. In addition, TLRY faces tough market share comps, where it has retraced from peak levels to stabilize following the completion of the merger with Aphria.”\n</blockquote>\n<p>Alliance Global Partners has a neutral recommendation on TLRY. Less optimistic, the analyst has lowered the target price from $32 to $18.Accordingto him, the merger with Aphria is beneficial for the stock, but the price is fair at current levels.</p>\n<p><b>Reddit popularity</b></p>\n<p>Tilray stock witnessed an eye-popping rally in February 2021. Shares climbed more than 670% between early January and early February, before pulling back sharply.</p>\n<p>The drivers of bullishness were (1) good earnings results, (2) favorable&nbsp;developments&nbsp;in cannabis regulation, and (2) the signed&nbsp;agreement&nbsp;with Grow Pharma to distribute medical cannabis for patients in the U.K.</p>\n<p>Reddit forums certainly seem to have played a role as well. Meme mania picked up steam in late January, at first with GameStop. Soon enough, other stocks like TLRY also benefited. See below the share price history, alongside the volume of comments on WallStreetBets.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/12016274a218bd36961f141e5af0556b\" tg-width=\"1160\" tg-height=\"840\" width=\"100%\" height=\"auto\"><span>Figure 4: TLRY stock sentiment and popularity on the WSB.</span></p>\n<p><b>Wall Street Memes’ take</b></p>\n<p>The cannabis industry is very sensitive to regulatory factors. Lack of positive news regarding new cannabis regulations can lead to prolonged periods of malaise in stock price, like the current one. In addition, Tilray faces the usual integration risks, following the recent merger.</p>\n<p>At the same time, opportunities continue to exist as medicinal and recreational use of cannabis in the U.S and elsewhere globally expand. Judging by stock ratings and price targets, Wall Street analysts still seem optimistic about the stock. Lastly, with the Reddit crowd paying attention, TLRY could potentially become the target of a meme attack again in the future.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray Stock: Buy Ahead Of Earnings?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray Stock: Buy Ahead Of Earnings?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 23:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.\nDrug manufacturer Tilray,...</p>\n\n<a href=\"https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc."},"source_url":"https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134472085","content_text":"On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.\nDrug manufacturer Tilray, a Canadian-based company engaged in research, cultivation, and distribution of medical cannabis, is about to report its fiscal fourth quarter results.\nThe stock has been popular among Redditors in 2021. With earnings day around the corner, the question now is whether TLRY might be a good buy at current prices.\nThe cannabis market\nIn the United States, a total of 34 states plus the District of Columbia consider marijuana legal for medicinal use. Among these, 16 have approved recreational use,according to the latest data.\nIn 2020, the cannabis market was estimated to be valued at $20 billion by New Frontier Data, and it is projected to reach $43 billion by 2025. Growth seems to be fueled by social acceptance of cannabis and the development of a regulatory framework for production.\nFigure 1: Annual growth of the U.S legal cannabis industry.\nTilray + Aphria merger\nTilray has been trading publicly since December 2020, after merging with Aphria. Following the deal, TLRY now has a market cap of close to $6 billion – one of the largest cannabis companies today, alongside peer Canopy Growth.\nThe Tilray-Aphria merger was justified by expected benefits that included:\n\nmarket leadership in Canada\nfoothold in Europe and better positioning in the U.S.\nlower production costs and synergies\n\nFigure 2: Aphria + Tilray merger.\nWall Street's take\nIn the past several quarters, Tilray has been making good strides on its P&L. In 2020, the company reported progressively better revenue that reached $210 million for the year. It also managed to reverse a sharp net loss position that had been accumulating since prior to last year. See below:\nFigure 3: Tilray earnings and revenues.\nAnalysts currently rate TLRY as a moderate buy, with an average target price of nearly $21 for a potential upside of 52%. The merger with Aphria weighed positively for most analysts.\nDespite the encouraging metrics, some of Wall Street’s commentary around the company and stock has been cautious lately. Last month, Cowen & Co.’s analyst maintained her buy recommendation, but stated the following about Tilray:\n\n \"We are taking down our revenue and EBITDA estimates, as we expect COVID challenges in Canada to remain a headwind. In addition, TLRY faces tough market share comps, where it has retraced from peak levels to stabilize following the completion of the merger with Aphria.”\n\nAlliance Global Partners has a neutral recommendation on TLRY. Less optimistic, the analyst has lowered the target price from $32 to $18.Accordingto him, the merger with Aphria is beneficial for the stock, but the price is fair at current levels.\nReddit popularity\nTilray stock witnessed an eye-popping rally in February 2021. Shares climbed more than 670% between early January and early February, before pulling back sharply.\nThe drivers of bullishness were (1) good earnings results, (2) favorable developments in cannabis regulation, and (2) the signed agreement with Grow Pharma to distribute medical cannabis for patients in the U.K.\nReddit forums certainly seem to have played a role as well. Meme mania picked up steam in late January, at first with GameStop. Soon enough, other stocks like TLRY also benefited. See below the share price history, alongside the volume of comments on WallStreetBets.\nFigure 4: TLRY stock sentiment and popularity on the WSB.\nWall Street Memes’ take\nThe cannabis industry is very sensitive to regulatory factors. Lack of positive news regarding new cannabis regulations can lead to prolonged periods of malaise in stock price, like the current one. In addition, Tilray faces the usual integration risks, following the recent merger.\nAt the same time, opportunities continue to exist as medicinal and recreational use of cannabis in the U.S and elsewhere globally expand. Judging by stock ratings and price targets, Wall Street analysts still seem optimistic about the stock. Lastly, with the Reddit crowd paying attention, TLRY could potentially become the target of a meme attack again in the future.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":803192165,"gmtCreate":1627427169857,"gmtModify":1703489560982,"author":{"id":"4089409912576010","authorId":"4089409912576010","name":"BBKK","avatar":"https://static.tigerbbs.com/50e16ff101160c30777ec2fc744874fc","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Wow&nbsp;","listText":"Wow&nbsp;","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/803192165","repostId":1134472085,"repostType":4,"repost":{"id":"1134472085","pubTimestamp":1627398407,"share":"https://www.laohu8.com/m/news/1134472085?lang=&edition=full","pubTime":"2021-07-27 23:06","market":"us","language":"en","title":"Tilray Stock: Buy Ahead Of Earnings?","url":"https://stock-news.laohu8.com/highlight/detail?id=1134472085","media":"TheStreet","summary":"On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. ","content":"<p>On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.</p>\n<p>Drug manufacturer Tilray, a Canadian-based company engaged in research, cultivation, and distribution of medical cannabis, is about to report its fiscal fourth quarter results.</p>\n<p>The stock has been popular among Redditors in 2021. With earnings day around the corner, the question now is whether TLRY might be a good buy at current prices.</p>\n<p><b>The cannabis market</b></p>\n<p>In the United States, a total of 34 states plus the District of Columbia consider marijuana legal for medicinal use. Among these, 16 have approved recreational use,according&nbsp;to the latest data.</p>\n<p>In 2020, the cannabis market was&nbsp;estimated&nbsp;to be valued at $20 billion by New Frontier Data, and it is projected to reach $43 billion by 2025. Growth seems to be fueled by social acceptance of cannabis and the development of a regulatory framework for production.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/703f3ea081e0c6f7d74ae53891810b24\" tg-width=\"1240\" tg-height=\"859\" width=\"100%\" height=\"auto\"><span>Figure 1: Annual growth of the U.S legal cannabis industry.</span></p>\n<p><b>Tilray + Aphria merger</b></p>\n<p>Tilray has been trading publicly since December 2020, after merging with Aphria. Following the deal, TLRY now has a market cap of close to $6 billion – one of the largest cannabis companies today, alongside peer Canopy Growth.</p>\n<p>The Tilray-Aphria merger was justified by expected benefits that included:</p>\n<ol>\n <li>market leadership in Canada</li>\n <li>foothold in Europe and better positioning in the U.S.</li>\n <li>lower production costs and synergies</li>\n</ol>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b6577d25764f8877328fad35a1d14e2d\" tg-width=\"1240\" tg-height=\"659\" width=\"100%\" height=\"auto\"><span>Figure 2: Aphria + Tilray merger.</span></p>\n<p><b>Wall Street's take</b></p>\n<p>In the past several quarters, Tilray has been making good strides on its P&amp;L. In 2020, the company reported progressively better revenue that reached $210 million for the year. It also managed to reverse a sharp net loss position that had been accumulating since prior to last year. See below:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2ee35f0e1943629cac6c9a31ffdb5ca8\" tg-width=\"1240\" tg-height=\"481\" width=\"100%\" height=\"auto\"><span>Figure 3: Tilray earnings and revenues.</span></p>\n<p>Analysts currently rate TLRY as a moderate buy, with an average target price of nearly $21 for a potential upside of 52%. The merger with Aphria weighed positively for most analysts.</p>\n<p>Despite the encouraging metrics, some of Wall Street’s commentary around the company and stock has been cautious lately. Last month, Cowen &amp; Co.’s analyst&nbsp;maintained&nbsp;her buy recommendation, but stated the following about Tilray:</p>\n<blockquote>\n \"We are taking down our revenue and EBITDA estimates, as we expect COVID challenges in Canada to remain a headwind. In addition, TLRY faces tough market share comps, where it has retraced from peak levels to stabilize following the completion of the merger with Aphria.”\n</blockquote>\n<p>Alliance Global Partners has a neutral recommendation on TLRY. Less optimistic, the analyst has lowered the target price from $32 to $18.Accordingto him, the merger with Aphria is beneficial for the stock, but the price is fair at current levels.</p>\n<p><b>Reddit popularity</b></p>\n<p>Tilray stock witnessed an eye-popping rally in February 2021. Shares climbed more than 670% between early January and early February, before pulling back sharply.</p>\n<p>The drivers of bullishness were (1) good earnings results, (2) favorable&nbsp;developments&nbsp;in cannabis regulation, and (2) the signed&nbsp;agreement&nbsp;with Grow Pharma to distribute medical cannabis for patients in the U.K.</p>\n<p>Reddit forums certainly seem to have played a role as well. Meme mania picked up steam in late January, at first with GameStop. Soon enough, other stocks like TLRY also benefited. See below the share price history, alongside the volume of comments on WallStreetBets.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/12016274a218bd36961f141e5af0556b\" tg-width=\"1160\" tg-height=\"840\" width=\"100%\" height=\"auto\"><span>Figure 4: TLRY stock sentiment and popularity on the WSB.</span></p>\n<p><b>Wall Street Memes’ take</b></p>\n<p>The cannabis industry is very sensitive to regulatory factors. Lack of positive news regarding new cannabis regulations can lead to prolonged periods of malaise in stock price, like the current one. In addition, Tilray faces the usual integration risks, following the recent merger.</p>\n<p>At the same time, opportunities continue to exist as medicinal and recreational use of cannabis in the U.S and elsewhere globally expand. Judging by stock ratings and price targets, Wall Street analysts still seem optimistic about the stock. Lastly, with the Reddit crowd paying attention, TLRY could potentially become the target of a meme attack again in the future.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray Stock: Buy Ahead Of Earnings?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray Stock: Buy Ahead Of Earnings?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 23:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.\nDrug manufacturer Tilray,...</p>\n\n<a href=\"https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc."},"source_url":"https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134472085","content_text":"On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.\nDrug manufacturer Tilray, a Canadian-based company engaged in research, cultivation, and distribution of medical cannabis, is about to report its fiscal fourth quarter results.\nThe stock has been popular among Redditors in 2021. With earnings day around the corner, the question now is whether TLRY might be a good buy at current prices.\nThe cannabis market\nIn the United States, a total of 34 states plus the District of Columbia consider marijuana legal for medicinal use. Among these, 16 have approved recreational use,according to the latest data.\nIn 2020, the cannabis market was estimated to be valued at $20 billion by New Frontier Data, and it is projected to reach $43 billion by 2025. Growth seems to be fueled by social acceptance of cannabis and the development of a regulatory framework for production.\nFigure 1: Annual growth of the U.S legal cannabis industry.\nTilray + Aphria merger\nTilray has been trading publicly since December 2020, after merging with Aphria. Following the deal, TLRY now has a market cap of close to $6 billion – one of the largest cannabis companies today, alongside peer Canopy Growth.\nThe Tilray-Aphria merger was justified by expected benefits that included:\n\nmarket leadership in Canada\nfoothold in Europe and better positioning in the U.S.\nlower production costs and synergies\n\nFigure 2: Aphria + Tilray merger.\nWall Street's take\nIn the past several quarters, Tilray has been making good strides on its P&L. In 2020, the company reported progressively better revenue that reached $210 million for the year. It also managed to reverse a sharp net loss position that had been accumulating since prior to last year. See below:\nFigure 3: Tilray earnings and revenues.\nAnalysts currently rate TLRY as a moderate buy, with an average target price of nearly $21 for a potential upside of 52%. The merger with Aphria weighed positively for most analysts.\nDespite the encouraging metrics, some of Wall Street’s commentary around the company and stock has been cautious lately. Last month, Cowen & Co.’s analyst maintained her buy recommendation, but stated the following about Tilray:\n\n \"We are taking down our revenue and EBITDA estimates, as we expect COVID challenges in Canada to remain a headwind. In addition, TLRY faces tough market share comps, where it has retraced from peak levels to stabilize following the completion of the merger with Aphria.”\n\nAlliance Global Partners has a neutral recommendation on TLRY. Less optimistic, the analyst has lowered the target price from $32 to $18.Accordingto him, the merger with Aphria is beneficial for the stock, but the price is fair at current levels.\nReddit popularity\nTilray stock witnessed an eye-popping rally in February 2021. Shares climbed more than 670% between early January and early February, before pulling back sharply.\nThe drivers of bullishness were (1) good earnings results, (2) favorable developments in cannabis regulation, and (2) the signed agreement with Grow Pharma to distribute medical cannabis for patients in the U.K.\nReddit forums certainly seem to have played a role as well. Meme mania picked up steam in late January, at first with GameStop. Soon enough, other stocks like TLRY also benefited. See below the share price history, alongside the volume of comments on WallStreetBets.\nFigure 4: TLRY stock sentiment and popularity on the WSB.\nWall Street Memes’ take\nThe cannabis industry is very sensitive to regulatory factors. Lack of positive news regarding new cannabis regulations can lead to prolonged periods of malaise in stock price, like the current one. In addition, Tilray faces the usual integration risks, following the recent merger.\nAt the same time, opportunities continue to exist as medicinal and recreational use of cannabis in the U.S and elsewhere globally expand. Judging by stock ratings and price targets, Wall Street analysts still seem optimistic about the stock. Lastly, with the Reddit crowd paying attention, TLRY could potentially become the target of a meme attack again in the future.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5351333,"gmtCreate":1627427833171,"gmtModify":1663231591260,"authorId":3574901428369611,"author":{"id":3574901428369611,"authorId":3574901428369611,"name":"Dbw","avatar":"https://static.tigerbbs.com/b2b540981c00cc0005e6241f782bd3c5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":803192165,"type":1,"supId":0,"prevId":0,"content":"yeah <u>wow</u>","text":"yeah <u>wow</u>","html":"yeah <u>wow</u>"}],"langContent":"EN"},{"id":803370870,"gmtCreate":1627425663490,"gmtModify":1703489522838,"author":{"id":"3573731928321338","authorId":"3573731928321338","name":"claratan","avatar":"https://static.tigerbbs.com/9c6bbdac9048ff2e4b740f272576e2be","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Wow ??","listText":"Wow ??","text":"Wow ??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/803370870","repostId":1134472085,"repostType":4,"repost":{"id":"1134472085","pubTimestamp":1627398407,"share":"https://www.laohu8.com/m/news/1134472085?lang=&edition=full","pubTime":"2021-07-27 23:06","market":"us","language":"en","title":"Tilray Stock: Buy Ahead Of Earnings?","url":"https://stock-news.laohu8.com/highlight/detail?id=1134472085","media":"TheStreet","summary":"On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. ","content":"<p>On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.</p>\n<p>Drug manufacturer Tilray, a Canadian-based company engaged in research, cultivation, and distribution of medical cannabis, is about to report its fiscal fourth quarter results.</p>\n<p>The stock has been popular among Redditors in 2021. With earnings day around the corner, the question now is whether TLRY might be a good buy at current prices.</p>\n<p><b>The cannabis market</b></p>\n<p>In the United States, a total of 34 states plus the District of Columbia consider marijuana legal for medicinal use. Among these, 16 have approved recreational use,according&nbsp;to the latest data.</p>\n<p>In 2020, the cannabis market was&nbsp;estimated&nbsp;to be valued at $20 billion by New Frontier Data, and it is projected to reach $43 billion by 2025. Growth seems to be fueled by social acceptance of cannabis and the development of a regulatory framework for production.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/703f3ea081e0c6f7d74ae53891810b24\" tg-width=\"1240\" tg-height=\"859\" width=\"100%\" height=\"auto\"><span>Figure 1: Annual growth of the U.S legal cannabis industry.</span></p>\n<p><b>Tilray + Aphria merger</b></p>\n<p>Tilray has been trading publicly since December 2020, after merging with Aphria. Following the deal, TLRY now has a market cap of close to $6 billion – one of the largest cannabis companies today, alongside peer Canopy Growth.</p>\n<p>The Tilray-Aphria merger was justified by expected benefits that included:</p>\n<ol>\n <li>market leadership in Canada</li>\n <li>foothold in Europe and better positioning in the U.S.</li>\n <li>lower production costs and synergies</li>\n</ol>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b6577d25764f8877328fad35a1d14e2d\" tg-width=\"1240\" tg-height=\"659\" width=\"100%\" height=\"auto\"><span>Figure 2: Aphria + Tilray merger.</span></p>\n<p><b>Wall Street's take</b></p>\n<p>In the past several quarters, Tilray has been making good strides on its P&amp;L. In 2020, the company reported progressively better revenue that reached $210 million for the year. It also managed to reverse a sharp net loss position that had been accumulating since prior to last year. See below:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2ee35f0e1943629cac6c9a31ffdb5ca8\" tg-width=\"1240\" tg-height=\"481\" width=\"100%\" height=\"auto\"><span>Figure 3: Tilray earnings and revenues.</span></p>\n<p>Analysts currently rate TLRY as a moderate buy, with an average target price of nearly $21 for a potential upside of 52%. The merger with Aphria weighed positively for most analysts.</p>\n<p>Despite the encouraging metrics, some of Wall Street’s commentary around the company and stock has been cautious lately. Last month, Cowen &amp; Co.’s analyst&nbsp;maintained&nbsp;her buy recommendation, but stated the following about Tilray:</p>\n<blockquote>\n \"We are taking down our revenue and EBITDA estimates, as we expect COVID challenges in Canada to remain a headwind. In addition, TLRY faces tough market share comps, where it has retraced from peak levels to stabilize following the completion of the merger with Aphria.”\n</blockquote>\n<p>Alliance Global Partners has a neutral recommendation on TLRY. Less optimistic, the analyst has lowered the target price from $32 to $18.Accordingto him, the merger with Aphria is beneficial for the stock, but the price is fair at current levels.</p>\n<p><b>Reddit popularity</b></p>\n<p>Tilray stock witnessed an eye-popping rally in February 2021. Shares climbed more than 670% between early January and early February, before pulling back sharply.</p>\n<p>The drivers of bullishness were (1) good earnings results, (2) favorable&nbsp;developments&nbsp;in cannabis regulation, and (2) the signed&nbsp;agreement&nbsp;with Grow Pharma to distribute medical cannabis for patients in the U.K.</p>\n<p>Reddit forums certainly seem to have played a role as well. Meme mania picked up steam in late January, at first with GameStop. Soon enough, other stocks like TLRY also benefited. See below the share price history, alongside the volume of comments on WallStreetBets.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/12016274a218bd36961f141e5af0556b\" tg-width=\"1160\" tg-height=\"840\" width=\"100%\" height=\"auto\"><span>Figure 4: TLRY stock sentiment and popularity on the WSB.</span></p>\n<p><b>Wall Street Memes’ take</b></p>\n<p>The cannabis industry is very sensitive to regulatory factors. Lack of positive news regarding new cannabis regulations can lead to prolonged periods of malaise in stock price, like the current one. In addition, Tilray faces the usual integration risks, following the recent merger.</p>\n<p>At the same time, opportunities continue to exist as medicinal and recreational use of cannabis in the U.S and elsewhere globally expand. Judging by stock ratings and price targets, Wall Street analysts still seem optimistic about the stock. Lastly, with the Reddit crowd paying attention, TLRY could potentially become the target of a meme attack again in the future.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray Stock: Buy Ahead Of Earnings?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray Stock: Buy Ahead Of Earnings?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 23:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.\nDrug manufacturer Tilray,...</p>\n\n<a href=\"https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc."},"source_url":"https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134472085","content_text":"On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.\nDrug manufacturer Tilray, a Canadian-based company engaged in research, cultivation, and distribution of medical cannabis, is about to report its fiscal fourth quarter results.\nThe stock has been popular among Redditors in 2021. With earnings day around the corner, the question now is whether TLRY might be a good buy at current prices.\nThe cannabis market\nIn the United States, a total of 34 states plus the District of Columbia consider marijuana legal for medicinal use. Among these, 16 have approved recreational use,according to the latest data.\nIn 2020, the cannabis market was estimated to be valued at $20 billion by New Frontier Data, and it is projected to reach $43 billion by 2025. Growth seems to be fueled by social acceptance of cannabis and the development of a regulatory framework for production.\nFigure 1: Annual growth of the U.S legal cannabis industry.\nTilray + Aphria merger\nTilray has been trading publicly since December 2020, after merging with Aphria. Following the deal, TLRY now has a market cap of close to $6 billion – one of the largest cannabis companies today, alongside peer Canopy Growth.\nThe Tilray-Aphria merger was justified by expected benefits that included:\n\nmarket leadership in Canada\nfoothold in Europe and better positioning in the U.S.\nlower production costs and synergies\n\nFigure 2: Aphria + Tilray merger.\nWall Street's take\nIn the past several quarters, Tilray has been making good strides on its P&L. In 2020, the company reported progressively better revenue that reached $210 million for the year. It also managed to reverse a sharp net loss position that had been accumulating since prior to last year. See below:\nFigure 3: Tilray earnings and revenues.\nAnalysts currently rate TLRY as a moderate buy, with an average target price of nearly $21 for a potential upside of 52%. The merger with Aphria weighed positively for most analysts.\nDespite the encouraging metrics, some of Wall Street’s commentary around the company and stock has been cautious lately. Last month, Cowen & Co.’s analyst maintained her buy recommendation, but stated the following about Tilray:\n\n \"We are taking down our revenue and EBITDA estimates, as we expect COVID challenges in Canada to remain a headwind. In addition, TLRY faces tough market share comps, where it has retraced from peak levels to stabilize following the completion of the merger with Aphria.”\n\nAlliance Global Partners has a neutral recommendation on TLRY. Less optimistic, the analyst has lowered the target price from $32 to $18.Accordingto him, the merger with Aphria is beneficial for the stock, but the price is fair at current levels.\nReddit popularity\nTilray stock witnessed an eye-popping rally in February 2021. Shares climbed more than 670% between early January and early February, before pulling back sharply.\nThe drivers of bullishness were (1) good earnings results, (2) favorable developments in cannabis regulation, and (2) the signed agreement with Grow Pharma to distribute medical cannabis for patients in the U.K.\nReddit forums certainly seem to have played a role as well. Meme mania picked up steam in late January, at first with GameStop. Soon enough, other stocks like TLRY also benefited. See below the share price history, alongside the volume of comments on WallStreetBets.\nFigure 4: TLRY stock sentiment and popularity on the WSB.\nWall Street Memes’ take\nThe cannabis industry is very sensitive to regulatory factors. Lack of positive news regarding new cannabis regulations can lead to prolonged periods of malaise in stock price, like the current one. In addition, Tilray faces the usual integration risks, following the recent merger.\nAt the same time, opportunities continue to exist as medicinal and recreational use of cannabis in the U.S and elsewhere globally expand. Judging by stock ratings and price targets, Wall Street analysts still seem optimistic about the stock. Lastly, with the Reddit crowd paying attention, TLRY could potentially become the target of a meme attack again in the future.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5351106,"gmtCreate":1627426907050,"gmtModify":1663231591548,"authorId":3582053708073909,"author":{"id":3582053708073909,"authorId":3582053708073909,"name":"WeiChyi","avatar":"https://static.tigerbbs.com/1215c6c4b4962560ae3ef6fe8d752a11","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":803370870,"type":1,"supId":0,"prevId":0,"content":"K","text":"K","html":"K"}],"langContent":"EN"},{"id":803327080,"gmtCreate":1627423958440,"gmtModify":1703489493526,"author":{"id":"3586310553293679","authorId":"3586310553293679","name":"SaberNoTooth","avatar":"https://community-static.tradeup.com/news/0e76511083610259e2add7e6e0f7ad6c","vip":1,"hat":"https://static.tigerbbs.com/f84859c65fc2d7681e28f6b8e9b0535a","crmLevel":6,"crmLevelSwitch":0},"htmlText":"pls like. thanks","listText":"pls like. thanks","text":"pls like. thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/803327080","repostId":1134472085,"repostType":4,"repost":{"id":"1134472085","pubTimestamp":1627398407,"share":"https://www.laohu8.com/m/news/1134472085?lang=&edition=full","pubTime":"2021-07-27 23:06","market":"us","language":"en","title":"Tilray Stock: Buy Ahead Of Earnings?","url":"https://stock-news.laohu8.com/highlight/detail?id=1134472085","media":"TheStreet","summary":"On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. ","content":"<p>On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.</p>\n<p>Drug manufacturer Tilray, a Canadian-based company engaged in research, cultivation, and distribution of medical cannabis, is about to report its fiscal fourth quarter results.</p>\n<p>The stock has been popular among Redditors in 2021. With earnings day around the corner, the question now is whether TLRY might be a good buy at current prices.</p>\n<p><b>The cannabis market</b></p>\n<p>In the United States, a total of 34 states plus the District of Columbia consider marijuana legal for medicinal use. Among these, 16 have approved recreational use,according&nbsp;to the latest data.</p>\n<p>In 2020, the cannabis market was&nbsp;estimated&nbsp;to be valued at $20 billion by New Frontier Data, and it is projected to reach $43 billion by 2025. Growth seems to be fueled by social acceptance of cannabis and the development of a regulatory framework for production.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/703f3ea081e0c6f7d74ae53891810b24\" tg-width=\"1240\" tg-height=\"859\" width=\"100%\" height=\"auto\"><span>Figure 1: Annual growth of the U.S legal cannabis industry.</span></p>\n<p><b>Tilray + Aphria merger</b></p>\n<p>Tilray has been trading publicly since December 2020, after merging with Aphria. Following the deal, TLRY now has a market cap of close to $6 billion – one of the largest cannabis companies today, alongside peer Canopy Growth.</p>\n<p>The Tilray-Aphria merger was justified by expected benefits that included:</p>\n<ol>\n <li>market leadership in Canada</li>\n <li>foothold in Europe and better positioning in the U.S.</li>\n <li>lower production costs and synergies</li>\n</ol>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b6577d25764f8877328fad35a1d14e2d\" tg-width=\"1240\" tg-height=\"659\" width=\"100%\" height=\"auto\"><span>Figure 2: Aphria + Tilray merger.</span></p>\n<p><b>Wall Street's take</b></p>\n<p>In the past several quarters, Tilray has been making good strides on its P&amp;L. In 2020, the company reported progressively better revenue that reached $210 million for the year. It also managed to reverse a sharp net loss position that had been accumulating since prior to last year. See below:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2ee35f0e1943629cac6c9a31ffdb5ca8\" tg-width=\"1240\" tg-height=\"481\" width=\"100%\" height=\"auto\"><span>Figure 3: Tilray earnings and revenues.</span></p>\n<p>Analysts currently rate TLRY as a moderate buy, with an average target price of nearly $21 for a potential upside of 52%. The merger with Aphria weighed positively for most analysts.</p>\n<p>Despite the encouraging metrics, some of Wall Street’s commentary around the company and stock has been cautious lately. Last month, Cowen &amp; Co.’s analyst&nbsp;maintained&nbsp;her buy recommendation, but stated the following about Tilray:</p>\n<blockquote>\n \"We are taking down our revenue and EBITDA estimates, as we expect COVID challenges in Canada to remain a headwind. In addition, TLRY faces tough market share comps, where it has retraced from peak levels to stabilize following the completion of the merger with Aphria.”\n</blockquote>\n<p>Alliance Global Partners has a neutral recommendation on TLRY. Less optimistic, the analyst has lowered the target price from $32 to $18.Accordingto him, the merger with Aphria is beneficial for the stock, but the price is fair at current levels.</p>\n<p><b>Reddit popularity</b></p>\n<p>Tilray stock witnessed an eye-popping rally in February 2021. Shares climbed more than 670% between early January and early February, before pulling back sharply.</p>\n<p>The drivers of bullishness were (1) good earnings results, (2) favorable&nbsp;developments&nbsp;in cannabis regulation, and (2) the signed&nbsp;agreement&nbsp;with Grow Pharma to distribute medical cannabis for patients in the U.K.</p>\n<p>Reddit forums certainly seem to have played a role as well. Meme mania picked up steam in late January, at first with GameStop. Soon enough, other stocks like TLRY also benefited. See below the share price history, alongside the volume of comments on WallStreetBets.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/12016274a218bd36961f141e5af0556b\" tg-width=\"1160\" tg-height=\"840\" width=\"100%\" height=\"auto\"><span>Figure 4: TLRY stock sentiment and popularity on the WSB.</span></p>\n<p><b>Wall Street Memes’ take</b></p>\n<p>The cannabis industry is very sensitive to regulatory factors. Lack of positive news regarding new cannabis regulations can lead to prolonged periods of malaise in stock price, like the current one. In addition, Tilray faces the usual integration risks, following the recent merger.</p>\n<p>At the same time, opportunities continue to exist as medicinal and recreational use of cannabis in the U.S and elsewhere globally expand. Judging by stock ratings and price targets, Wall Street analysts still seem optimistic about the stock. Lastly, with the Reddit crowd paying attention, TLRY could potentially become the target of a meme attack again in the future.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray Stock: Buy Ahead Of Earnings?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray Stock: Buy Ahead Of Earnings?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 23:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.\nDrug manufacturer Tilray,...</p>\n\n<a href=\"https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc."},"source_url":"https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134472085","content_text":"On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.\nDrug manufacturer Tilray, a Canadian-based company engaged in research, cultivation, and distribution of medical cannabis, is about to report its fiscal fourth quarter results.\nThe stock has been popular among Redditors in 2021. With earnings day around the corner, the question now is whether TLRY might be a good buy at current prices.\nThe cannabis market\nIn the United States, a total of 34 states plus the District of Columbia consider marijuana legal for medicinal use. Among these, 16 have approved recreational use,according to the latest data.\nIn 2020, the cannabis market was estimated to be valued at $20 billion by New Frontier Data, and it is projected to reach $43 billion by 2025. Growth seems to be fueled by social acceptance of cannabis and the development of a regulatory framework for production.\nFigure 1: Annual growth of the U.S legal cannabis industry.\nTilray + Aphria merger\nTilray has been trading publicly since December 2020, after merging with Aphria. Following the deal, TLRY now has a market cap of close to $6 billion – one of the largest cannabis companies today, alongside peer Canopy Growth.\nThe Tilray-Aphria merger was justified by expected benefits that included:\n\nmarket leadership in Canada\nfoothold in Europe and better positioning in the U.S.\nlower production costs and synergies\n\nFigure 2: Aphria + Tilray merger.\nWall Street's take\nIn the past several quarters, Tilray has been making good strides on its P&L. In 2020, the company reported progressively better revenue that reached $210 million for the year. It also managed to reverse a sharp net loss position that had been accumulating since prior to last year. See below:\nFigure 3: Tilray earnings and revenues.\nAnalysts currently rate TLRY as a moderate buy, with an average target price of nearly $21 for a potential upside of 52%. The merger with Aphria weighed positively for most analysts.\nDespite the encouraging metrics, some of Wall Street’s commentary around the company and stock has been cautious lately. Last month, Cowen & Co.’s analyst maintained her buy recommendation, but stated the following about Tilray:\n\n \"We are taking down our revenue and EBITDA estimates, as we expect COVID challenges in Canada to remain a headwind. In addition, TLRY faces tough market share comps, where it has retraced from peak levels to stabilize following the completion of the merger with Aphria.”\n\nAlliance Global Partners has a neutral recommendation on TLRY. Less optimistic, the analyst has lowered the target price from $32 to $18.Accordingto him, the merger with Aphria is beneficial for the stock, but the price is fair at current levels.\nReddit popularity\nTilray stock witnessed an eye-popping rally in February 2021. Shares climbed more than 670% between early January and early February, before pulling back sharply.\nThe drivers of bullishness were (1) good earnings results, (2) favorable developments in cannabis regulation, and (2) the signed agreement with Grow Pharma to distribute medical cannabis for patients in the U.K.\nReddit forums certainly seem to have played a role as well. Meme mania picked up steam in late January, at first with GameStop. Soon enough, other stocks like TLRY also benefited. See below the share price history, alongside the volume of comments on WallStreetBets.\nFigure 4: TLRY stock sentiment and popularity on the WSB.\nWall Street Memes’ take\nThe cannabis industry is very sensitive to regulatory factors. Lack of positive news regarding new cannabis regulations can lead to prolonged periods of malaise in stock price, like the current one. In addition, Tilray faces the usual integration risks, following the recent merger.\nAt the same time, opportunities continue to exist as medicinal and recreational use of cannabis in the U.S and elsewhere globally expand. Judging by stock ratings and price targets, Wall Street analysts still seem optimistic about the stock. Lastly, with the Reddit crowd paying attention, TLRY could potentially become the target of a meme attack again in the future.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":803321112,"gmtCreate":1627423255136,"gmtModify":1703489484438,"author":{"id":"3580768650075144","authorId":"3580768650075144","name":"Derrickmin","avatar":"https://static.tigerbbs.com/3bb88321eb16bafea5d8794f4409690e","vip":1,"hat":"https://static.tigerbbs.com/ae1f49570794979e009a5efdeb6f4789","crmLevel":1,"crmLevelSwitch":0},"htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/803321112","repostId":1134472085,"repostType":4,"repost":{"id":"1134472085","pubTimestamp":1627398407,"share":"https://www.laohu8.com/m/news/1134472085?lang=&edition=full","pubTime":"2021-07-27 23:06","market":"us","language":"en","title":"Tilray Stock: Buy Ahead Of Earnings?","url":"https://stock-news.laohu8.com/highlight/detail?id=1134472085","media":"TheStreet","summary":"On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. ","content":"<p>On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.</p>\n<p>Drug manufacturer Tilray, a Canadian-based company engaged in research, cultivation, and distribution of medical cannabis, is about to report its fiscal fourth quarter results.</p>\n<p>The stock has been popular among Redditors in 2021. With earnings day around the corner, the question now is whether TLRY might be a good buy at current prices.</p>\n<p><b>The cannabis market</b></p>\n<p>In the United States, a total of 34 states plus the District of Columbia consider marijuana legal for medicinal use. Among these, 16 have approved recreational use,according&nbsp;to the latest data.</p>\n<p>In 2020, the cannabis market was&nbsp;estimated&nbsp;to be valued at $20 billion by New Frontier Data, and it is projected to reach $43 billion by 2025. Growth seems to be fueled by social acceptance of cannabis and the development of a regulatory framework for production.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/703f3ea081e0c6f7d74ae53891810b24\" tg-width=\"1240\" tg-height=\"859\" width=\"100%\" height=\"auto\"><span>Figure 1: Annual growth of the U.S legal cannabis industry.</span></p>\n<p><b>Tilray + Aphria merger</b></p>\n<p>Tilray has been trading publicly since December 2020, after merging with Aphria. Following the deal, TLRY now has a market cap of close to $6 billion – one of the largest cannabis companies today, alongside peer Canopy Growth.</p>\n<p>The Tilray-Aphria merger was justified by expected benefits that included:</p>\n<ol>\n <li>market leadership in Canada</li>\n <li>foothold in Europe and better positioning in the U.S.</li>\n <li>lower production costs and synergies</li>\n</ol>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b6577d25764f8877328fad35a1d14e2d\" tg-width=\"1240\" tg-height=\"659\" width=\"100%\" height=\"auto\"><span>Figure 2: Aphria + Tilray merger.</span></p>\n<p><b>Wall Street's take</b></p>\n<p>In the past several quarters, Tilray has been making good strides on its P&amp;L. In 2020, the company reported progressively better revenue that reached $210 million for the year. It also managed to reverse a sharp net loss position that had been accumulating since prior to last year. See below:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2ee35f0e1943629cac6c9a31ffdb5ca8\" tg-width=\"1240\" tg-height=\"481\" width=\"100%\" height=\"auto\"><span>Figure 3: Tilray earnings and revenues.</span></p>\n<p>Analysts currently rate TLRY as a moderate buy, with an average target price of nearly $21 for a potential upside of 52%. The merger with Aphria weighed positively for most analysts.</p>\n<p>Despite the encouraging metrics, some of Wall Street’s commentary around the company and stock has been cautious lately. Last month, Cowen &amp; Co.’s analyst&nbsp;maintained&nbsp;her buy recommendation, but stated the following about Tilray:</p>\n<blockquote>\n \"We are taking down our revenue and EBITDA estimates, as we expect COVID challenges in Canada to remain a headwind. In addition, TLRY faces tough market share comps, where it has retraced from peak levels to stabilize following the completion of the merger with Aphria.”\n</blockquote>\n<p>Alliance Global Partners has a neutral recommendation on TLRY. Less optimistic, the analyst has lowered the target price from $32 to $18.Accordingto him, the merger with Aphria is beneficial for the stock, but the price is fair at current levels.</p>\n<p><b>Reddit popularity</b></p>\n<p>Tilray stock witnessed an eye-popping rally in February 2021. Shares climbed more than 670% between early January and early February, before pulling back sharply.</p>\n<p>The drivers of bullishness were (1) good earnings results, (2) favorable&nbsp;developments&nbsp;in cannabis regulation, and (2) the signed&nbsp;agreement&nbsp;with Grow Pharma to distribute medical cannabis for patients in the U.K.</p>\n<p>Reddit forums certainly seem to have played a role as well. Meme mania picked up steam in late January, at first with GameStop. Soon enough, other stocks like TLRY also benefited. See below the share price history, alongside the volume of comments on WallStreetBets.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/12016274a218bd36961f141e5af0556b\" tg-width=\"1160\" tg-height=\"840\" width=\"100%\" height=\"auto\"><span>Figure 4: TLRY stock sentiment and popularity on the WSB.</span></p>\n<p><b>Wall Street Memes’ take</b></p>\n<p>The cannabis industry is very sensitive to regulatory factors. Lack of positive news regarding new cannabis regulations can lead to prolonged periods of malaise in stock price, like the current one. In addition, Tilray faces the usual integration risks, following the recent merger.</p>\n<p>At the same time, opportunities continue to exist as medicinal and recreational use of cannabis in the U.S and elsewhere globally expand. Judging by stock ratings and price targets, Wall Street analysts still seem optimistic about the stock. Lastly, with the Reddit crowd paying attention, TLRY could potentially become the target of a meme attack again in the future.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray Stock: Buy Ahead Of Earnings?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray Stock: Buy Ahead Of Earnings?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 23:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.\nDrug manufacturer Tilray,...</p>\n\n<a href=\"https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc."},"source_url":"https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134472085","content_text":"On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.\nDrug manufacturer Tilray, a Canadian-based company engaged in research, cultivation, and distribution of medical cannabis, is about to report its fiscal fourth quarter results.\nThe stock has been popular among Redditors in 2021. With earnings day around the corner, the question now is whether TLRY might be a good buy at current prices.\nThe cannabis market\nIn the United States, a total of 34 states plus the District of Columbia consider marijuana legal for medicinal use. Among these, 16 have approved recreational use,according to the latest data.\nIn 2020, the cannabis market was estimated to be valued at $20 billion by New Frontier Data, and it is projected to reach $43 billion by 2025. Growth seems to be fueled by social acceptance of cannabis and the development of a regulatory framework for production.\nFigure 1: Annual growth of the U.S legal cannabis industry.\nTilray + Aphria merger\nTilray has been trading publicly since December 2020, after merging with Aphria. Following the deal, TLRY now has a market cap of close to $6 billion – one of the largest cannabis companies today, alongside peer Canopy Growth.\nThe Tilray-Aphria merger was justified by expected benefits that included:\n\nmarket leadership in Canada\nfoothold in Europe and better positioning in the U.S.\nlower production costs and synergies\n\nFigure 2: Aphria + Tilray merger.\nWall Street's take\nIn the past several quarters, Tilray has been making good strides on its P&L. In 2020, the company reported progressively better revenue that reached $210 million for the year. It also managed to reverse a sharp net loss position that had been accumulating since prior to last year. See below:\nFigure 3: Tilray earnings and revenues.\nAnalysts currently rate TLRY as a moderate buy, with an average target price of nearly $21 for a potential upside of 52%. The merger with Aphria weighed positively for most analysts.\nDespite the encouraging metrics, some of Wall Street’s commentary around the company and stock has been cautious lately. Last month, Cowen & Co.’s analyst maintained her buy recommendation, but stated the following about Tilray:\n\n \"We are taking down our revenue and EBITDA estimates, as we expect COVID challenges in Canada to remain a headwind. In addition, TLRY faces tough market share comps, where it has retraced from peak levels to stabilize following the completion of the merger with Aphria.”\n\nAlliance Global Partners has a neutral recommendation on TLRY. Less optimistic, the analyst has lowered the target price from $32 to $18.Accordingto him, the merger with Aphria is beneficial for the stock, but the price is fair at current levels.\nReddit popularity\nTilray stock witnessed an eye-popping rally in February 2021. Shares climbed more than 670% between early January and early February, before pulling back sharply.\nThe drivers of bullishness were (1) good earnings results, (2) favorable developments in cannabis regulation, and (2) the signed agreement with Grow Pharma to distribute medical cannabis for patients in the U.K.\nReddit forums certainly seem to have played a role as well. Meme mania picked up steam in late January, at first with GameStop. Soon enough, other stocks like TLRY also benefited. See below the share price history, alongside the volume of comments on WallStreetBets.\nFigure 4: TLRY stock sentiment and popularity on the WSB.\nWall Street Memes’ take\nThe cannabis industry is very sensitive to regulatory factors. Lack of positive news regarding new cannabis regulations can lead to prolonged periods of malaise in stock price, like the current one. In addition, Tilray faces the usual integration risks, following the recent merger.\nAt the same time, opportunities continue to exist as medicinal and recreational use of cannabis in the U.S and elsewhere globally expand. Judging by stock ratings and price targets, Wall Street analysts still seem optimistic about the stock. Lastly, with the Reddit crowd paying attention, TLRY could potentially become the target of a meme attack again in the future.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":803331348,"gmtCreate":1627410669784,"gmtModify":1703489431008,"author":{"id":"4087547182018110","authorId":"4087547182018110","name":"RyanLJW","avatar":"https://static.tigerbbs.com/e396858878cea653fba7a9215fa2ca8f","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Amazing","listText":"Amazing","text":"Amazing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/803331348","repostId":1134472085,"repostType":4,"repost":{"id":"1134472085","pubTimestamp":1627398407,"share":"https://www.laohu8.com/m/news/1134472085?lang=&edition=full","pubTime":"2021-07-27 23:06","market":"us","language":"en","title":"Tilray Stock: Buy Ahead Of Earnings?","url":"https://stock-news.laohu8.com/highlight/detail?id=1134472085","media":"TheStreet","summary":"On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. ","content":"<p>On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.</p>\n<p>Drug manufacturer Tilray, a Canadian-based company engaged in research, cultivation, and distribution of medical cannabis, is about to report its fiscal fourth quarter results.</p>\n<p>The stock has been popular among Redditors in 2021. With earnings day around the corner, the question now is whether TLRY might be a good buy at current prices.</p>\n<p><b>The cannabis market</b></p>\n<p>In the United States, a total of 34 states plus the District of Columbia consider marijuana legal for medicinal use. Among these, 16 have approved recreational use,according&nbsp;to the latest data.</p>\n<p>In 2020, the cannabis market was&nbsp;estimated&nbsp;to be valued at $20 billion by New Frontier Data, and it is projected to reach $43 billion by 2025. Growth seems to be fueled by social acceptance of cannabis and the development of a regulatory framework for production.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/703f3ea081e0c6f7d74ae53891810b24\" tg-width=\"1240\" tg-height=\"859\" width=\"100%\" height=\"auto\"><span>Figure 1: Annual growth of the U.S legal cannabis industry.</span></p>\n<p><b>Tilray + Aphria merger</b></p>\n<p>Tilray has been trading publicly since December 2020, after merging with Aphria. Following the deal, TLRY now has a market cap of close to $6 billion – one of the largest cannabis companies today, alongside peer Canopy Growth.</p>\n<p>The Tilray-Aphria merger was justified by expected benefits that included:</p>\n<ol>\n <li>market leadership in Canada</li>\n <li>foothold in Europe and better positioning in the U.S.</li>\n <li>lower production costs and synergies</li>\n</ol>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b6577d25764f8877328fad35a1d14e2d\" tg-width=\"1240\" tg-height=\"659\" width=\"100%\" height=\"auto\"><span>Figure 2: Aphria + Tilray merger.</span></p>\n<p><b>Wall Street's take</b></p>\n<p>In the past several quarters, Tilray has been making good strides on its P&amp;L. In 2020, the company reported progressively better revenue that reached $210 million for the year. It also managed to reverse a sharp net loss position that had been accumulating since prior to last year. See below:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2ee35f0e1943629cac6c9a31ffdb5ca8\" tg-width=\"1240\" tg-height=\"481\" width=\"100%\" height=\"auto\"><span>Figure 3: Tilray earnings and revenues.</span></p>\n<p>Analysts currently rate TLRY as a moderate buy, with an average target price of nearly $21 for a potential upside of 52%. The merger with Aphria weighed positively for most analysts.</p>\n<p>Despite the encouraging metrics, some of Wall Street’s commentary around the company and stock has been cautious lately. Last month, Cowen &amp; Co.’s analyst&nbsp;maintained&nbsp;her buy recommendation, but stated the following about Tilray:</p>\n<blockquote>\n \"We are taking down our revenue and EBITDA estimates, as we expect COVID challenges in Canada to remain a headwind. In addition, TLRY faces tough market share comps, where it has retraced from peak levels to stabilize following the completion of the merger with Aphria.”\n</blockquote>\n<p>Alliance Global Partners has a neutral recommendation on TLRY. Less optimistic, the analyst has lowered the target price from $32 to $18.Accordingto him, the merger with Aphria is beneficial for the stock, but the price is fair at current levels.</p>\n<p><b>Reddit popularity</b></p>\n<p>Tilray stock witnessed an eye-popping rally in February 2021. Shares climbed more than 670% between early January and early February, before pulling back sharply.</p>\n<p>The drivers of bullishness were (1) good earnings results, (2) favorable&nbsp;developments&nbsp;in cannabis regulation, and (2) the signed&nbsp;agreement&nbsp;with Grow Pharma to distribute medical cannabis for patients in the U.K.</p>\n<p>Reddit forums certainly seem to have played a role as well. Meme mania picked up steam in late January, at first with GameStop. Soon enough, other stocks like TLRY also benefited. See below the share price history, alongside the volume of comments on WallStreetBets.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/12016274a218bd36961f141e5af0556b\" tg-width=\"1160\" tg-height=\"840\" width=\"100%\" height=\"auto\"><span>Figure 4: TLRY stock sentiment and popularity on the WSB.</span></p>\n<p><b>Wall Street Memes’ take</b></p>\n<p>The cannabis industry is very sensitive to regulatory factors. Lack of positive news regarding new cannabis regulations can lead to prolonged periods of malaise in stock price, like the current one. In addition, Tilray faces the usual integration risks, following the recent merger.</p>\n<p>At the same time, opportunities continue to exist as medicinal and recreational use of cannabis in the U.S and elsewhere globally expand. Judging by stock ratings and price targets, Wall Street analysts still seem optimistic about the stock. Lastly, with the Reddit crowd paying attention, TLRY could potentially become the target of a meme attack again in the future.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray Stock: Buy Ahead Of Earnings?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray Stock: Buy Ahead Of Earnings?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 23:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.\nDrug manufacturer Tilray,...</p>\n\n<a href=\"https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc."},"source_url":"https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134472085","content_text":"On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.\nDrug manufacturer Tilray, a Canadian-based company engaged in research, cultivation, and distribution of medical cannabis, is about to report its fiscal fourth quarter results.\nThe stock has been popular among Redditors in 2021. With earnings day around the corner, the question now is whether TLRY might be a good buy at current prices.\nThe cannabis market\nIn the United States, a total of 34 states plus the District of Columbia consider marijuana legal for medicinal use. Among these, 16 have approved recreational use,according to the latest data.\nIn 2020, the cannabis market was estimated to be valued at $20 billion by New Frontier Data, and it is projected to reach $43 billion by 2025. Growth seems to be fueled by social acceptance of cannabis and the development of a regulatory framework for production.\nFigure 1: Annual growth of the U.S legal cannabis industry.\nTilray + Aphria merger\nTilray has been trading publicly since December 2020, after merging with Aphria. Following the deal, TLRY now has a market cap of close to $6 billion – one of the largest cannabis companies today, alongside peer Canopy Growth.\nThe Tilray-Aphria merger was justified by expected benefits that included:\n\nmarket leadership in Canada\nfoothold in Europe and better positioning in the U.S.\nlower production costs and synergies\n\nFigure 2: Aphria + Tilray merger.\nWall Street's take\nIn the past several quarters, Tilray has been making good strides on its P&L. In 2020, the company reported progressively better revenue that reached $210 million for the year. It also managed to reverse a sharp net loss position that had been accumulating since prior to last year. See below:\nFigure 3: Tilray earnings and revenues.\nAnalysts currently rate TLRY as a moderate buy, with an average target price of nearly $21 for a potential upside of 52%. The merger with Aphria weighed positively for most analysts.\nDespite the encouraging metrics, some of Wall Street’s commentary around the company and stock has been cautious lately. Last month, Cowen & Co.’s analyst maintained her buy recommendation, but stated the following about Tilray:\n\n \"We are taking down our revenue and EBITDA estimates, as we expect COVID challenges in Canada to remain a headwind. In addition, TLRY faces tough market share comps, where it has retraced from peak levels to stabilize following the completion of the merger with Aphria.”\n\nAlliance Global Partners has a neutral recommendation on TLRY. Less optimistic, the analyst has lowered the target price from $32 to $18.Accordingto him, the merger with Aphria is beneficial for the stock, but the price is fair at current levels.\nReddit popularity\nTilray stock witnessed an eye-popping rally in February 2021. Shares climbed more than 670% between early January and early February, before pulling back sharply.\nThe drivers of bullishness were (1) good earnings results, (2) favorable developments in cannabis regulation, and (2) the signed agreement with Grow Pharma to distribute medical cannabis for patients in the U.K.\nReddit forums certainly seem to have played a role as well. Meme mania picked up steam in late January, at first with GameStop. Soon enough, other stocks like TLRY also benefited. See below the share price history, alongside the volume of comments on WallStreetBets.\nFigure 4: TLRY stock sentiment and popularity on the WSB.\nWall Street Memes’ take\nThe cannabis industry is very sensitive to regulatory factors. Lack of positive news regarding new cannabis regulations can lead to prolonged periods of malaise in stock price, like the current one. In addition, Tilray faces the usual integration risks, following the recent merger.\nAt the same time, opportunities continue to exist as medicinal and recreational use of cannabis in the U.S and elsewhere globally expand. Judging by stock ratings and price targets, Wall Street analysts still seem optimistic about the stock. Lastly, with the Reddit crowd paying attention, TLRY could potentially become the target of a meme attack again in the future.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":803989666,"gmtCreate":1627400913355,"gmtModify":1703489315805,"author":{"id":"3565164731962180","authorId":"3565164731962180","name":"eggyoke99","avatar":"https://static.tigerbbs.com/0674970c1706ae5097fbae0b807d0162","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"yeah","listText":"yeah","text":"yeah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/803989666","repostId":1134472085,"repostType":4,"repost":{"id":"1134472085","pubTimestamp":1627398407,"share":"https://www.laohu8.com/m/news/1134472085?lang=&edition=full","pubTime":"2021-07-27 23:06","market":"us","language":"en","title":"Tilray Stock: Buy Ahead Of Earnings?","url":"https://stock-news.laohu8.com/highlight/detail?id=1134472085","media":"TheStreet","summary":"On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. ","content":"<p>On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.</p>\n<p>Drug manufacturer Tilray, a Canadian-based company engaged in research, cultivation, and distribution of medical cannabis, is about to report its fiscal fourth quarter results.</p>\n<p>The stock has been popular among Redditors in 2021. With earnings day around the corner, the question now is whether TLRY might be a good buy at current prices.</p>\n<p><b>The cannabis market</b></p>\n<p>In the United States, a total of 34 states plus the District of Columbia consider marijuana legal for medicinal use. Among these, 16 have approved recreational use,according&nbsp;to the latest data.</p>\n<p>In 2020, the cannabis market was&nbsp;estimated&nbsp;to be valued at $20 billion by New Frontier Data, and it is projected to reach $43 billion by 2025. Growth seems to be fueled by social acceptance of cannabis and the development of a regulatory framework for production.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/703f3ea081e0c6f7d74ae53891810b24\" tg-width=\"1240\" tg-height=\"859\" width=\"100%\" height=\"auto\"><span>Figure 1: Annual growth of the U.S legal cannabis industry.</span></p>\n<p><b>Tilray + Aphria merger</b></p>\n<p>Tilray has been trading publicly since December 2020, after merging with Aphria. Following the deal, TLRY now has a market cap of close to $6 billion – one of the largest cannabis companies today, alongside peer Canopy Growth.</p>\n<p>The Tilray-Aphria merger was justified by expected benefits that included:</p>\n<ol>\n <li>market leadership in Canada</li>\n <li>foothold in Europe and better positioning in the U.S.</li>\n <li>lower production costs and synergies</li>\n</ol>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b6577d25764f8877328fad35a1d14e2d\" tg-width=\"1240\" tg-height=\"659\" width=\"100%\" height=\"auto\"><span>Figure 2: Aphria + Tilray merger.</span></p>\n<p><b>Wall Street's take</b></p>\n<p>In the past several quarters, Tilray has been making good strides on its P&amp;L. In 2020, the company reported progressively better revenue that reached $210 million for the year. It also managed to reverse a sharp net loss position that had been accumulating since prior to last year. See below:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2ee35f0e1943629cac6c9a31ffdb5ca8\" tg-width=\"1240\" tg-height=\"481\" width=\"100%\" height=\"auto\"><span>Figure 3: Tilray earnings and revenues.</span></p>\n<p>Analysts currently rate TLRY as a moderate buy, with an average target price of nearly $21 for a potential upside of 52%. The merger with Aphria weighed positively for most analysts.</p>\n<p>Despite the encouraging metrics, some of Wall Street’s commentary around the company and stock has been cautious lately. Last month, Cowen &amp; Co.’s analyst&nbsp;maintained&nbsp;her buy recommendation, but stated the following about Tilray:</p>\n<blockquote>\n \"We are taking down our revenue and EBITDA estimates, as we expect COVID challenges in Canada to remain a headwind. In addition, TLRY faces tough market share comps, where it has retraced from peak levels to stabilize following the completion of the merger with Aphria.”\n</blockquote>\n<p>Alliance Global Partners has a neutral recommendation on TLRY. Less optimistic, the analyst has lowered the target price from $32 to $18.Accordingto him, the merger with Aphria is beneficial for the stock, but the price is fair at current levels.</p>\n<p><b>Reddit popularity</b></p>\n<p>Tilray stock witnessed an eye-popping rally in February 2021. Shares climbed more than 670% between early January and early February, before pulling back sharply.</p>\n<p>The drivers of bullishness were (1) good earnings results, (2) favorable&nbsp;developments&nbsp;in cannabis regulation, and (2) the signed&nbsp;agreement&nbsp;with Grow Pharma to distribute medical cannabis for patients in the U.K.</p>\n<p>Reddit forums certainly seem to have played a role as well. Meme mania picked up steam in late January, at first with GameStop. Soon enough, other stocks like TLRY also benefited. See below the share price history, alongside the volume of comments on WallStreetBets.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/12016274a218bd36961f141e5af0556b\" tg-width=\"1160\" tg-height=\"840\" width=\"100%\" height=\"auto\"><span>Figure 4: TLRY stock sentiment and popularity on the WSB.</span></p>\n<p><b>Wall Street Memes’ take</b></p>\n<p>The cannabis industry is very sensitive to regulatory factors. Lack of positive news regarding new cannabis regulations can lead to prolonged periods of malaise in stock price, like the current one. In addition, Tilray faces the usual integration risks, following the recent merger.</p>\n<p>At the same time, opportunities continue to exist as medicinal and recreational use of cannabis in the U.S and elsewhere globally expand. Judging by stock ratings and price targets, Wall Street analysts still seem optimistic about the stock. Lastly, with the Reddit crowd paying attention, TLRY could potentially become the target of a meme attack again in the future.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray Stock: Buy Ahead Of Earnings?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray Stock: Buy Ahead Of Earnings?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 23:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.\nDrug manufacturer Tilray,...</p>\n\n<a href=\"https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc."},"source_url":"https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134472085","content_text":"On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.\nDrug manufacturer Tilray, a Canadian-based company engaged in research, cultivation, and distribution of medical cannabis, is about to report its fiscal fourth quarter results.\nThe stock has been popular among Redditors in 2021. With earnings day around the corner, the question now is whether TLRY might be a good buy at current prices.\nThe cannabis market\nIn the United States, a total of 34 states plus the District of Columbia consider marijuana legal for medicinal use. Among these, 16 have approved recreational use,according to the latest data.\nIn 2020, the cannabis market was estimated to be valued at $20 billion by New Frontier Data, and it is projected to reach $43 billion by 2025. Growth seems to be fueled by social acceptance of cannabis and the development of a regulatory framework for production.\nFigure 1: Annual growth of the U.S legal cannabis industry.\nTilray + Aphria merger\nTilray has been trading publicly since December 2020, after merging with Aphria. Following the deal, TLRY now has a market cap of close to $6 billion – one of the largest cannabis companies today, alongside peer Canopy Growth.\nThe Tilray-Aphria merger was justified by expected benefits that included:\n\nmarket leadership in Canada\nfoothold in Europe and better positioning in the U.S.\nlower production costs and synergies\n\nFigure 2: Aphria + Tilray merger.\nWall Street's take\nIn the past several quarters, Tilray has been making good strides on its P&L. In 2020, the company reported progressively better revenue that reached $210 million for the year. It also managed to reverse a sharp net loss position that had been accumulating since prior to last year. See below:\nFigure 3: Tilray earnings and revenues.\nAnalysts currently rate TLRY as a moderate buy, with an average target price of nearly $21 for a potential upside of 52%. The merger with Aphria weighed positively for most analysts.\nDespite the encouraging metrics, some of Wall Street’s commentary around the company and stock has been cautious lately. Last month, Cowen & Co.’s analyst maintained her buy recommendation, but stated the following about Tilray:\n\n \"We are taking down our revenue and EBITDA estimates, as we expect COVID challenges in Canada to remain a headwind. In addition, TLRY faces tough market share comps, where it has retraced from peak levels to stabilize following the completion of the merger with Aphria.”\n\nAlliance Global Partners has a neutral recommendation on TLRY. Less optimistic, the analyst has lowered the target price from $32 to $18.Accordingto him, the merger with Aphria is beneficial for the stock, but the price is fair at current levels.\nReddit popularity\nTilray stock witnessed an eye-popping rally in February 2021. Shares climbed more than 670% between early January and early February, before pulling back sharply.\nThe drivers of bullishness were (1) good earnings results, (2) favorable developments in cannabis regulation, and (2) the signed agreement with Grow Pharma to distribute medical cannabis for patients in the U.K.\nReddit forums certainly seem to have played a role as well. Meme mania picked up steam in late January, at first with GameStop. Soon enough, other stocks like TLRY also benefited. See below the share price history, alongside the volume of comments on WallStreetBets.\nFigure 4: TLRY stock sentiment and popularity on the WSB.\nWall Street Memes’ take\nThe cannabis industry is very sensitive to regulatory factors. Lack of positive news regarding new cannabis regulations can lead to prolonged periods of malaise in stock price, like the current one. In addition, Tilray faces the usual integration risks, following the recent merger.\nAt the same time, opportunities continue to exist as medicinal and recreational use of cannabis in the U.S and elsewhere globally expand. Judging by stock ratings and price targets, Wall Street analysts still seem optimistic about the stock. Lastly, with the Reddit crowd paying attention, TLRY could potentially become the target of a meme attack again in the future.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":803918025,"gmtCreate":1627400470367,"gmtModify":1703489305962,"author":{"id":"3581588474178431","authorId":"3581588474178431","name":"PanaCota","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Oo","listText":"Oo","text":"Oo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/803918025","repostId":1134472085,"repostType":4,"repost":{"id":"1134472085","pubTimestamp":1627398407,"share":"https://www.laohu8.com/m/news/1134472085?lang=&edition=full","pubTime":"2021-07-27 23:06","market":"us","language":"en","title":"Tilray Stock: Buy Ahead Of Earnings?","url":"https://stock-news.laohu8.com/highlight/detail?id=1134472085","media":"TheStreet","summary":"On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. ","content":"<p>On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.</p>\n<p>Drug manufacturer Tilray, a Canadian-based company engaged in research, cultivation, and distribution of medical cannabis, is about to report its fiscal fourth quarter results.</p>\n<p>The stock has been popular among Redditors in 2021. With earnings day around the corner, the question now is whether TLRY might be a good buy at current prices.</p>\n<p><b>The cannabis market</b></p>\n<p>In the United States, a total of 34 states plus the District of Columbia consider marijuana legal for medicinal use. Among these, 16 have approved recreational use,according&nbsp;to the latest data.</p>\n<p>In 2020, the cannabis market was&nbsp;estimated&nbsp;to be valued at $20 billion by New Frontier Data, and it is projected to reach $43 billion by 2025. Growth seems to be fueled by social acceptance of cannabis and the development of a regulatory framework for production.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/703f3ea081e0c6f7d74ae53891810b24\" tg-width=\"1240\" tg-height=\"859\" width=\"100%\" height=\"auto\"><span>Figure 1: Annual growth of the U.S legal cannabis industry.</span></p>\n<p><b>Tilray + Aphria merger</b></p>\n<p>Tilray has been trading publicly since December 2020, after merging with Aphria. Following the deal, TLRY now has a market cap of close to $6 billion – one of the largest cannabis companies today, alongside peer Canopy Growth.</p>\n<p>The Tilray-Aphria merger was justified by expected benefits that included:</p>\n<ol>\n <li>market leadership in Canada</li>\n <li>foothold in Europe and better positioning in the U.S.</li>\n <li>lower production costs and synergies</li>\n</ol>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b6577d25764f8877328fad35a1d14e2d\" tg-width=\"1240\" tg-height=\"659\" width=\"100%\" height=\"auto\"><span>Figure 2: Aphria + Tilray merger.</span></p>\n<p><b>Wall Street's take</b></p>\n<p>In the past several quarters, Tilray has been making good strides on its P&amp;L. In 2020, the company reported progressively better revenue that reached $210 million for the year. It also managed to reverse a sharp net loss position that had been accumulating since prior to last year. See below:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2ee35f0e1943629cac6c9a31ffdb5ca8\" tg-width=\"1240\" tg-height=\"481\" width=\"100%\" height=\"auto\"><span>Figure 3: Tilray earnings and revenues.</span></p>\n<p>Analysts currently rate TLRY as a moderate buy, with an average target price of nearly $21 for a potential upside of 52%. The merger with Aphria weighed positively for most analysts.</p>\n<p>Despite the encouraging metrics, some of Wall Street’s commentary around the company and stock has been cautious lately. Last month, Cowen &amp; Co.’s analyst&nbsp;maintained&nbsp;her buy recommendation, but stated the following about Tilray:</p>\n<blockquote>\n \"We are taking down our revenue and EBITDA estimates, as we expect COVID challenges in Canada to remain a headwind. In addition, TLRY faces tough market share comps, where it has retraced from peak levels to stabilize following the completion of the merger with Aphria.”\n</blockquote>\n<p>Alliance Global Partners has a neutral recommendation on TLRY. Less optimistic, the analyst has lowered the target price from $32 to $18.Accordingto him, the merger with Aphria is beneficial for the stock, but the price is fair at current levels.</p>\n<p><b>Reddit popularity</b></p>\n<p>Tilray stock witnessed an eye-popping rally in February 2021. Shares climbed more than 670% between early January and early February, before pulling back sharply.</p>\n<p>The drivers of bullishness were (1) good earnings results, (2) favorable&nbsp;developments&nbsp;in cannabis regulation, and (2) the signed&nbsp;agreement&nbsp;with Grow Pharma to distribute medical cannabis for patients in the U.K.</p>\n<p>Reddit forums certainly seem to have played a role as well. Meme mania picked up steam in late January, at first with GameStop. Soon enough, other stocks like TLRY also benefited. See below the share price history, alongside the volume of comments on WallStreetBets.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/12016274a218bd36961f141e5af0556b\" tg-width=\"1160\" tg-height=\"840\" width=\"100%\" height=\"auto\"><span>Figure 4: TLRY stock sentiment and popularity on the WSB.</span></p>\n<p><b>Wall Street Memes’ take</b></p>\n<p>The cannabis industry is very sensitive to regulatory factors. Lack of positive news regarding new cannabis regulations can lead to prolonged periods of malaise in stock price, like the current one. In addition, Tilray faces the usual integration risks, following the recent merger.</p>\n<p>At the same time, opportunities continue to exist as medicinal and recreational use of cannabis in the U.S and elsewhere globally expand. Judging by stock ratings and price targets, Wall Street analysts still seem optimistic about the stock. Lastly, with the Reddit crowd paying attention, TLRY could potentially become the target of a meme attack again in the future.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray Stock: Buy Ahead Of Earnings?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray Stock: Buy Ahead Of Earnings?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 23:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.\nDrug manufacturer Tilray,...</p>\n\n<a href=\"https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc."},"source_url":"https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134472085","content_text":"On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.\nDrug manufacturer Tilray, a Canadian-based company engaged in research, cultivation, and distribution of medical cannabis, is about to report its fiscal fourth quarter results.\nThe stock has been popular among Redditors in 2021. With earnings day around the corner, the question now is whether TLRY might be a good buy at current prices.\nThe cannabis market\nIn the United States, a total of 34 states plus the District of Columbia consider marijuana legal for medicinal use. Among these, 16 have approved recreational use,according to the latest data.\nIn 2020, the cannabis market was estimated to be valued at $20 billion by New Frontier Data, and it is projected to reach $43 billion by 2025. Growth seems to be fueled by social acceptance of cannabis and the development of a regulatory framework for production.\nFigure 1: Annual growth of the U.S legal cannabis industry.\nTilray + Aphria merger\nTilray has been trading publicly since December 2020, after merging with Aphria. Following the deal, TLRY now has a market cap of close to $6 billion – one of the largest cannabis companies today, alongside peer Canopy Growth.\nThe Tilray-Aphria merger was justified by expected benefits that included:\n\nmarket leadership in Canada\nfoothold in Europe and better positioning in the U.S.\nlower production costs and synergies\n\nFigure 2: Aphria + Tilray merger.\nWall Street's take\nIn the past several quarters, Tilray has been making good strides on its P&L. In 2020, the company reported progressively better revenue that reached $210 million for the year. It also managed to reverse a sharp net loss position that had been accumulating since prior to last year. See below:\nFigure 3: Tilray earnings and revenues.\nAnalysts currently rate TLRY as a moderate buy, with an average target price of nearly $21 for a potential upside of 52%. The merger with Aphria weighed positively for most analysts.\nDespite the encouraging metrics, some of Wall Street’s commentary around the company and stock has been cautious lately. Last month, Cowen & Co.’s analyst maintained her buy recommendation, but stated the following about Tilray:\n\n \"We are taking down our revenue and EBITDA estimates, as we expect COVID challenges in Canada to remain a headwind. In addition, TLRY faces tough market share comps, where it has retraced from peak levels to stabilize following the completion of the merger with Aphria.”\n\nAlliance Global Partners has a neutral recommendation on TLRY. Less optimistic, the analyst has lowered the target price from $32 to $18.Accordingto him, the merger with Aphria is beneficial for the stock, but the price is fair at current levels.\nReddit popularity\nTilray stock witnessed an eye-popping rally in February 2021. Shares climbed more than 670% between early January and early February, before pulling back sharply.\nThe drivers of bullishness were (1) good earnings results, (2) favorable developments in cannabis regulation, and (2) the signed agreement with Grow Pharma to distribute medical cannabis for patients in the U.K.\nReddit forums certainly seem to have played a role as well. Meme mania picked up steam in late January, at first with GameStop. Soon enough, other stocks like TLRY also benefited. See below the share price history, alongside the volume of comments on WallStreetBets.\nFigure 4: TLRY stock sentiment and popularity on the WSB.\nWall Street Memes’ take\nThe cannabis industry is very sensitive to regulatory factors. Lack of positive news regarding new cannabis regulations can lead to prolonged periods of malaise in stock price, like the current one. In addition, Tilray faces the usual integration risks, following the recent merger.\nAt the same time, opportunities continue to exist as medicinal and recreational use of cannabis in the U.S and elsewhere globally expand. Judging by stock ratings and price targets, Wall Street analysts still seem optimistic about the stock. Lastly, with the Reddit crowd paying attention, TLRY could potentially become the target of a meme attack again in the future.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5358348,"gmtCreate":1627476535945,"gmtModify":1663231624827,"authorId":3581562365927542,"author":{"id":3581562365927542,"authorId":3581562365927542,"name":"BBBBBBBBBB","avatar":"https://static.tigerbbs.com/973395458d7e1db24dbd4a689c79e8a2","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":803918025,"type":1,"supId":0,"prevId":0,"content":"Hi","text":"Hi","html":"Hi"}],"langContent":"EN"},{"id":803073138,"gmtCreate":1627398533224,"gmtModify":1703489248066,"author":{"id":"3581992421704233","authorId":"3581992421704233","name":"Chrissssy","avatar":"https://static.tigerbbs.com/670519b0df7f01f6802e6a220a6fc578","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Like and comment please:)","listText":"Like and comment please:)","text":"Like and comment please:)","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/803073138","repostId":1134472085,"repostType":4,"repost":{"id":"1134472085","pubTimestamp":1627398407,"share":"https://www.laohu8.com/m/news/1134472085?lang=&edition=full","pubTime":"2021-07-27 23:06","market":"us","language":"en","title":"Tilray Stock: Buy Ahead Of Earnings?","url":"https://stock-news.laohu8.com/highlight/detail?id=1134472085","media":"TheStreet","summary":"On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. ","content":"<p>On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.</p>\n<p>Drug manufacturer Tilray, a Canadian-based company engaged in research, cultivation, and distribution of medical cannabis, is about to report its fiscal fourth quarter results.</p>\n<p>The stock has been popular among Redditors in 2021. With earnings day around the corner, the question now is whether TLRY might be a good buy at current prices.</p>\n<p><b>The cannabis market</b></p>\n<p>In the United States, a total of 34 states plus the District of Columbia consider marijuana legal for medicinal use. Among these, 16 have approved recreational use,according&nbsp;to the latest data.</p>\n<p>In 2020, the cannabis market was&nbsp;estimated&nbsp;to be valued at $20 billion by New Frontier Data, and it is projected to reach $43 billion by 2025. Growth seems to be fueled by social acceptance of cannabis and the development of a regulatory framework for production.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/703f3ea081e0c6f7d74ae53891810b24\" tg-width=\"1240\" tg-height=\"859\" width=\"100%\" height=\"auto\"><span>Figure 1: Annual growth of the U.S legal cannabis industry.</span></p>\n<p><b>Tilray + Aphria merger</b></p>\n<p>Tilray has been trading publicly since December 2020, after merging with Aphria. Following the deal, TLRY now has a market cap of close to $6 billion – one of the largest cannabis companies today, alongside peer Canopy Growth.</p>\n<p>The Tilray-Aphria merger was justified by expected benefits that included:</p>\n<ol>\n <li>market leadership in Canada</li>\n <li>foothold in Europe and better positioning in the U.S.</li>\n <li>lower production costs and synergies</li>\n</ol>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b6577d25764f8877328fad35a1d14e2d\" tg-width=\"1240\" tg-height=\"659\" width=\"100%\" height=\"auto\"><span>Figure 2: Aphria + Tilray merger.</span></p>\n<p><b>Wall Street's take</b></p>\n<p>In the past several quarters, Tilray has been making good strides on its P&amp;L. In 2020, the company reported progressively better revenue that reached $210 million for the year. It also managed to reverse a sharp net loss position that had been accumulating since prior to last year. See below:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2ee35f0e1943629cac6c9a31ffdb5ca8\" tg-width=\"1240\" tg-height=\"481\" width=\"100%\" height=\"auto\"><span>Figure 3: Tilray earnings and revenues.</span></p>\n<p>Analysts currently rate TLRY as a moderate buy, with an average target price of nearly $21 for a potential upside of 52%. The merger with Aphria weighed positively for most analysts.</p>\n<p>Despite the encouraging metrics, some of Wall Street’s commentary around the company and stock has been cautious lately. Last month, Cowen &amp; Co.’s analyst&nbsp;maintained&nbsp;her buy recommendation, but stated the following about Tilray:</p>\n<blockquote>\n \"We are taking down our revenue and EBITDA estimates, as we expect COVID challenges in Canada to remain a headwind. In addition, TLRY faces tough market share comps, where it has retraced from peak levels to stabilize following the completion of the merger with Aphria.”\n</blockquote>\n<p>Alliance Global Partners has a neutral recommendation on TLRY. Less optimistic, the analyst has lowered the target price from $32 to $18.Accordingto him, the merger with Aphria is beneficial for the stock, but the price is fair at current levels.</p>\n<p><b>Reddit popularity</b></p>\n<p>Tilray stock witnessed an eye-popping rally in February 2021. Shares climbed more than 670% between early January and early February, before pulling back sharply.</p>\n<p>The drivers of bullishness were (1) good earnings results, (2) favorable&nbsp;developments&nbsp;in cannabis regulation, and (2) the signed&nbsp;agreement&nbsp;with Grow Pharma to distribute medical cannabis for patients in the U.K.</p>\n<p>Reddit forums certainly seem to have played a role as well. Meme mania picked up steam in late January, at first with GameStop. Soon enough, other stocks like TLRY also benefited. See below the share price history, alongside the volume of comments on WallStreetBets.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/12016274a218bd36961f141e5af0556b\" tg-width=\"1160\" tg-height=\"840\" width=\"100%\" height=\"auto\"><span>Figure 4: TLRY stock sentiment and popularity on the WSB.</span></p>\n<p><b>Wall Street Memes’ take</b></p>\n<p>The cannabis industry is very sensitive to regulatory factors. Lack of positive news regarding new cannabis regulations can lead to prolonged periods of malaise in stock price, like the current one. In addition, Tilray faces the usual integration risks, following the recent merger.</p>\n<p>At the same time, opportunities continue to exist as medicinal and recreational use of cannabis in the U.S and elsewhere globally expand. Judging by stock ratings and price targets, Wall Street analysts still seem optimistic about the stock. Lastly, with the Reddit crowd paying attention, TLRY could potentially become the target of a meme attack again in the future.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray Stock: Buy Ahead Of Earnings?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray Stock: Buy Ahead Of Earnings?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 23:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.\nDrug manufacturer Tilray,...</p>\n\n<a href=\"https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc."},"source_url":"https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134472085","content_text":"On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.\nDrug manufacturer Tilray, a Canadian-based company engaged in research, cultivation, and distribution of medical cannabis, is about to report its fiscal fourth quarter results.\nThe stock has been popular among Redditors in 2021. With earnings day around the corner, the question now is whether TLRY might be a good buy at current prices.\nThe cannabis market\nIn the United States, a total of 34 states plus the District of Columbia consider marijuana legal for medicinal use. Among these, 16 have approved recreational use,according to the latest data.\nIn 2020, the cannabis market was estimated to be valued at $20 billion by New Frontier Data, and it is projected to reach $43 billion by 2025. Growth seems to be fueled by social acceptance of cannabis and the development of a regulatory framework for production.\nFigure 1: Annual growth of the U.S legal cannabis industry.\nTilray + Aphria merger\nTilray has been trading publicly since December 2020, after merging with Aphria. Following the deal, TLRY now has a market cap of close to $6 billion – one of the largest cannabis companies today, alongside peer Canopy Growth.\nThe Tilray-Aphria merger was justified by expected benefits that included:\n\nmarket leadership in Canada\nfoothold in Europe and better positioning in the U.S.\nlower production costs and synergies\n\nFigure 2: Aphria + Tilray merger.\nWall Street's take\nIn the past several quarters, Tilray has been making good strides on its P&L. In 2020, the company reported progressively better revenue that reached $210 million for the year. It also managed to reverse a sharp net loss position that had been accumulating since prior to last year. See below:\nFigure 3: Tilray earnings and revenues.\nAnalysts currently rate TLRY as a moderate buy, with an average target price of nearly $21 for a potential upside of 52%. The merger with Aphria weighed positively for most analysts.\nDespite the encouraging metrics, some of Wall Street’s commentary around the company and stock has been cautious lately. Last month, Cowen & Co.’s analyst maintained her buy recommendation, but stated the following about Tilray:\n\n \"We are taking down our revenue and EBITDA estimates, as we expect COVID challenges in Canada to remain a headwind. In addition, TLRY faces tough market share comps, where it has retraced from peak levels to stabilize following the completion of the merger with Aphria.”\n\nAlliance Global Partners has a neutral recommendation on TLRY. Less optimistic, the analyst has lowered the target price from $32 to $18.Accordingto him, the merger with Aphria is beneficial for the stock, but the price is fair at current levels.\nReddit popularity\nTilray stock witnessed an eye-popping rally in February 2021. Shares climbed more than 670% between early January and early February, before pulling back sharply.\nThe drivers of bullishness were (1) good earnings results, (2) favorable developments in cannabis regulation, and (2) the signed agreement with Grow Pharma to distribute medical cannabis for patients in the U.K.\nReddit forums certainly seem to have played a role as well. Meme mania picked up steam in late January, at first with GameStop. Soon enough, other stocks like TLRY also benefited. See below the share price history, alongside the volume of comments on WallStreetBets.\nFigure 4: TLRY stock sentiment and popularity on the WSB.\nWall Street Memes’ take\nThe cannabis industry is very sensitive to regulatory factors. Lack of positive news regarding new cannabis regulations can lead to prolonged periods of malaise in stock price, like the current one. In addition, Tilray faces the usual integration risks, following the recent merger.\nAt the same time, opportunities continue to exist as medicinal and recreational use of cannabis in the U.S and elsewhere globally expand. Judging by stock ratings and price targets, Wall Street analysts still seem optimistic about the stock. Lastly, with the Reddit crowd paying attention, TLRY could potentially become the target of a meme attack again in the future.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5350625,"gmtCreate":1627423250249,"gmtModify":1663231589948,"authorId":3580768650075144,"author":{"id":3580768650075144,"authorId":3580768650075144,"name":"Derrickmin","avatar":"https://static.tigerbbs.com/3bb88321eb16bafea5d8794f4409690e","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":803073138,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"},{"id":5348833,"gmtCreate":1627398872767,"gmtModify":1663231578039,"authorId":3574210732047776,"author":{"id":3574210732047776,"authorId":3574210732047776,"name":"ykang","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":803073138,"type":1,"supId":0,"prevId":0,"content":"buy！","text":"buy！","html":"buy！"}],"langContent":"EN"},{"id":803079147,"gmtCreate":1627398494689,"gmtModify":1703489246904,"author":{"id":"3581984006176179","authorId":"3581984006176179","name":"kukumolu","avatar":"https://static.tigerbbs.com/968c9b6dacd85f184faef66f2db6a7a7","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"It should rise after the FUD","listText":"It should rise after the FUD","text":"It should rise after the FUD","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/803079147","repostId":1134472085,"repostType":4,"repost":{"id":"1134472085","pubTimestamp":1627398407,"share":"https://www.laohu8.com/m/news/1134472085?lang=&edition=full","pubTime":"2021-07-27 23:06","market":"us","language":"en","title":"Tilray Stock: Buy Ahead Of Earnings?","url":"https://stock-news.laohu8.com/highlight/detail?id=1134472085","media":"TheStreet","summary":"On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. ","content":"<p>On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.</p>\n<p>Drug manufacturer Tilray, a Canadian-based company engaged in research, cultivation, and distribution of medical cannabis, is about to report its fiscal fourth quarter results.</p>\n<p>The stock has been popular among Redditors in 2021. With earnings day around the corner, the question now is whether TLRY might be a good buy at current prices.</p>\n<p><b>The cannabis market</b></p>\n<p>In the United States, a total of 34 states plus the District of Columbia consider marijuana legal for medicinal use. Among these, 16 have approved recreational use,according&nbsp;to the latest data.</p>\n<p>In 2020, the cannabis market was&nbsp;estimated&nbsp;to be valued at $20 billion by New Frontier Data, and it is projected to reach $43 billion by 2025. Growth seems to be fueled by social acceptance of cannabis and the development of a regulatory framework for production.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/703f3ea081e0c6f7d74ae53891810b24\" tg-width=\"1240\" tg-height=\"859\" width=\"100%\" height=\"auto\"><span>Figure 1: Annual growth of the U.S legal cannabis industry.</span></p>\n<p><b>Tilray + Aphria merger</b></p>\n<p>Tilray has been trading publicly since December 2020, after merging with Aphria. Following the deal, TLRY now has a market cap of close to $6 billion – one of the largest cannabis companies today, alongside peer Canopy Growth.</p>\n<p>The Tilray-Aphria merger was justified by expected benefits that included:</p>\n<ol>\n <li>market leadership in Canada</li>\n <li>foothold in Europe and better positioning in the U.S.</li>\n <li>lower production costs and synergies</li>\n</ol>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b6577d25764f8877328fad35a1d14e2d\" tg-width=\"1240\" tg-height=\"659\" width=\"100%\" height=\"auto\"><span>Figure 2: Aphria + Tilray merger.</span></p>\n<p><b>Wall Street's take</b></p>\n<p>In the past several quarters, Tilray has been making good strides on its P&amp;L. In 2020, the company reported progressively better revenue that reached $210 million for the year. It also managed to reverse a sharp net loss position that had been accumulating since prior to last year. See below:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2ee35f0e1943629cac6c9a31ffdb5ca8\" tg-width=\"1240\" tg-height=\"481\" width=\"100%\" height=\"auto\"><span>Figure 3: Tilray earnings and revenues.</span></p>\n<p>Analysts currently rate TLRY as a moderate buy, with an average target price of nearly $21 for a potential upside of 52%. The merger with Aphria weighed positively for most analysts.</p>\n<p>Despite the encouraging metrics, some of Wall Street’s commentary around the company and stock has been cautious lately. Last month, Cowen &amp; Co.’s analyst&nbsp;maintained&nbsp;her buy recommendation, but stated the following about Tilray:</p>\n<blockquote>\n \"We are taking down our revenue and EBITDA estimates, as we expect COVID challenges in Canada to remain a headwind. In addition, TLRY faces tough market share comps, where it has retraced from peak levels to stabilize following the completion of the merger with Aphria.”\n</blockquote>\n<p>Alliance Global Partners has a neutral recommendation on TLRY. Less optimistic, the analyst has lowered the target price from $32 to $18.Accordingto him, the merger with Aphria is beneficial for the stock, but the price is fair at current levels.</p>\n<p><b>Reddit popularity</b></p>\n<p>Tilray stock witnessed an eye-popping rally in February 2021. Shares climbed more than 670% between early January and early February, before pulling back sharply.</p>\n<p>The drivers of bullishness were (1) good earnings results, (2) favorable&nbsp;developments&nbsp;in cannabis regulation, and (2) the signed&nbsp;agreement&nbsp;with Grow Pharma to distribute medical cannabis for patients in the U.K.</p>\n<p>Reddit forums certainly seem to have played a role as well. Meme mania picked up steam in late January, at first with GameStop. Soon enough, other stocks like TLRY also benefited. See below the share price history, alongside the volume of comments on WallStreetBets.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/12016274a218bd36961f141e5af0556b\" tg-width=\"1160\" tg-height=\"840\" width=\"100%\" height=\"auto\"><span>Figure 4: TLRY stock sentiment and popularity on the WSB.</span></p>\n<p><b>Wall Street Memes’ take</b></p>\n<p>The cannabis industry is very sensitive to regulatory factors. Lack of positive news regarding new cannabis regulations can lead to prolonged periods of malaise in stock price, like the current one. In addition, Tilray faces the usual integration risks, following the recent merger.</p>\n<p>At the same time, opportunities continue to exist as medicinal and recreational use of cannabis in the U.S and elsewhere globally expand. Judging by stock ratings and price targets, Wall Street analysts still seem optimistic about the stock. Lastly, with the Reddit crowd paying attention, TLRY could potentially become the target of a meme attack again in the future.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray Stock: Buy Ahead Of Earnings?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray Stock: Buy Ahead Of Earnings?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 23:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.\nDrug manufacturer Tilray,...</p>\n\n<a href=\"https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc."},"source_url":"https://www.thestreet.com/memestocks/other-memes/tilray-stock-buy-ahead-of-earnings","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134472085","content_text":"On Wednesday, July 28, drug manufacturer Tilray will report fiscal fourth quarter earnings results. Wall Street Memes discusses whether this may be a good buying opportunity.\nDrug manufacturer Tilray, a Canadian-based company engaged in research, cultivation, and distribution of medical cannabis, is about to report its fiscal fourth quarter results.\nThe stock has been popular among Redditors in 2021. With earnings day around the corner, the question now is whether TLRY might be a good buy at current prices.\nThe cannabis market\nIn the United States, a total of 34 states plus the District of Columbia consider marijuana legal for medicinal use. Among these, 16 have approved recreational use,according to the latest data.\nIn 2020, the cannabis market was estimated to be valued at $20 billion by New Frontier Data, and it is projected to reach $43 billion by 2025. Growth seems to be fueled by social acceptance of cannabis and the development of a regulatory framework for production.\nFigure 1: Annual growth of the U.S legal cannabis industry.\nTilray + Aphria merger\nTilray has been trading publicly since December 2020, after merging with Aphria. Following the deal, TLRY now has a market cap of close to $6 billion – one of the largest cannabis companies today, alongside peer Canopy Growth.\nThe Tilray-Aphria merger was justified by expected benefits that included:\n\nmarket leadership in Canada\nfoothold in Europe and better positioning in the U.S.\nlower production costs and synergies\n\nFigure 2: Aphria + Tilray merger.\nWall Street's take\nIn the past several quarters, Tilray has been making good strides on its P&L. In 2020, the company reported progressively better revenue that reached $210 million for the year. It also managed to reverse a sharp net loss position that had been accumulating since prior to last year. See below:\nFigure 3: Tilray earnings and revenues.\nAnalysts currently rate TLRY as a moderate buy, with an average target price of nearly $21 for a potential upside of 52%. The merger with Aphria weighed positively for most analysts.\nDespite the encouraging metrics, some of Wall Street’s commentary around the company and stock has been cautious lately. Last month, Cowen & Co.’s analyst maintained her buy recommendation, but stated the following about Tilray:\n\n \"We are taking down our revenue and EBITDA estimates, as we expect COVID challenges in Canada to remain a headwind. In addition, TLRY faces tough market share comps, where it has retraced from peak levels to stabilize following the completion of the merger with Aphria.”\n\nAlliance Global Partners has a neutral recommendation on TLRY. Less optimistic, the analyst has lowered the target price from $32 to $18.Accordingto him, the merger with Aphria is beneficial for the stock, but the price is fair at current levels.\nReddit popularity\nTilray stock witnessed an eye-popping rally in February 2021. Shares climbed more than 670% between early January and early February, before pulling back sharply.\nThe drivers of bullishness were (1) good earnings results, (2) favorable developments in cannabis regulation, and (2) the signed agreement with Grow Pharma to distribute medical cannabis for patients in the U.K.\nReddit forums certainly seem to have played a role as well. Meme mania picked up steam in late January, at first with GameStop. Soon enough, other stocks like TLRY also benefited. See below the share price history, alongside the volume of comments on WallStreetBets.\nFigure 4: TLRY stock sentiment and popularity on the WSB.\nWall Street Memes’ take\nThe cannabis industry is very sensitive to regulatory factors. Lack of positive news regarding new cannabis regulations can lead to prolonged periods of malaise in stock price, like the current one. In addition, Tilray faces the usual integration risks, following the recent merger.\nAt the same time, opportunities continue to exist as medicinal and recreational use of cannabis in the U.S and elsewhere globally expand. Judging by stock ratings and price targets, Wall Street analysts still seem optimistic about the stock. Lastly, with the Reddit crowd paying attention, TLRY could potentially become the target of a meme attack again in the future.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":96,"commentSize":10,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false}}